Skip to content

OTC · CIK 0000072444

VXRT Vaxart, Inc.

Insider trading from SEC Form 4. Last filing Jul 20, 2026. Close $0.43 on Oct 9, 2026, +30% from the 52-week low and -46% from the high.

In brief

Vaxart, Inc. (VXRT) has 48 SEC Form 4 filings on file from 10 insiders, the latest filed on Jul 20, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

6 open-market trades have been scored at VXRT. The newest: W. Mark Watson (director) bought $6,530 of stock on May 22, 2026, filed May 26, 2026, scored 22 (weak). The largest of the 6 shown: Kevin Finney (director) bought $62k on Jul 17, 2025, scored 40 (moderate). 2 insiders bought within 14 days of each other around Nov 17, 2025.

2 Form 144 notices of planned sales are on file, the latest filed Dec 8, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company

Price and insider trades, last year

VXRTOct 9, 2026 · close 0.43

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Vaxart, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
22WeakW. Mark Watson
director
buy
$6,530
10,000 shares
+8%+113% from low-20% from high
26WeakW. Mark Watson
director
buy
$8,185
20,000 shares
+19%-
33WeakElaine J Heron
director
buy
$16k
40,000 shares
+71%-
40ModerateKevin Finney
director
buy
$62k
166,668 shares
+437%-
26WeakW. Mark Watson
director
buy
$4,050
10,000 shares
+11%-
40ModerateSteven Lo
President, Chief Exec Officer
buy
$49k
100,000 shares
--

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Dec 8, 2025 MICHAEL JOSEPH FINNEY
Former Director
40,000
0.02% of outstanding
$14kDec 8, 2025$35k
May 27, 2025 Lee Phillip E (VXRT)
Former Executive Officer
81,364
0.04% of outstanding
$37kMay 27, 2025none

Transactions

The newest 50 of 79 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jul 16, 2026Kevin Finney
director
AGrant or award
Common Stock
+39,400$0.00$0244,171Jul 20, 2026
Jul 16, 2026Kevin Finney
director
AGrant or award
Stock Options (right to buy)derivative
+78,700$0.00$078,700Jul 20, 2026
Jul 16, 2026David E. Wheadon
director
AGrant or award
Common Stock
+39,400$0.00$086,150Jul 17, 2026
Jul 16, 2026W. Mark Watson
director
AGrant or award
Common Stock
+39,400$0.00$0173,525Jul 17, 2026
Jul 16, 2026Elaine J Heron
director
AGrant or award
Common Stock
+39,400$0.00$0135,966Jul 17, 2026
Jul 16, 2026James B Breitmeyer
director
AGrant or award
Common Stock
+8,315$0.00$087,115Jul 17, 2026
Jul 16, 2026David E. Wheadon
director
AGrant or award
Stock Options (right to buy)derivative
+78,700$0.00$078,700Jul 17, 2026
Jul 16, 2026Elaine J Heron
director
AGrant or award
Stock Options (right to buy)derivative
+78,700$0.00$078,700Jul 17, 2026
Jul 16, 2026James B Breitmeyer
director
AGrant or award
Stock Options (right to buy)derivative
+16,610$0.00$016,610Jul 17, 2026
Jul 16, 2026W. Mark Watson
director
AGrant or award
Stock Options (right to buy)derivative
+78,700$0.00$078,700Jul 17, 2026
May 22, 2026W. Mark Watson
director
POpen-market purchase
Common Stock
+10,000$0.65$6,530134,125May 26, 2026
May 19, 2026Jeroen Nicolaas Grasman
Chief Financial Officer
FTax withholding
Common Stock
-31,395$0.61$19k545,605May 21, 2026
Apr 23, 2026James B Breitmeyer
director
AGrant or award
Common Stock
+78,800$0.00$078,800May 1, 2026
Apr 23, 2026James B Breitmeyer
director
AGrant or award
Stock Option (right to buy)derivative
+157,400$0.00$0157,400May 1, 2026
Mar 28, 2026Sean Tucker
SVP, Chief Scientific Officer
FTax withholding
Common Stock
-3,924$0.65$2,551882,811Mar 31, 2026
Mar 28, 2026James F. Cummings
Chief Medical Officer
FTax withholding
Common Stock
-3,292$0.65$2,140924,177Mar 31, 2026
Mar 24, 2026Edward B Berg
SVP, General Counsel
FTax withholding
Common Stock
-36,418$0.69$25k755,368Mar 26, 2026
Mar 24, 2026James F. Cummings
Chief Medical Officer
FTax withholding
Common Stock
-30,551$0.69$21k927,469Mar 26, 2026
Mar 24, 2026Steven Lo
President, Chief Exec Officer
FTax withholding
Common Stock
-126,028$0.69$87k2,485,606Mar 26, 2026
Mar 24, 2026Sean Tucker
SVP, Chief Scientific Officer
FTax withholding
Common Stock
-36,418$0.69$25k886,735Mar 26, 2026
Mar 18, 2026Edward B Berg
SVP, General Counsel
FTax withholding
Common Stock
-8,072$0.63$5,122791,786Mar 20, 2026
Mar 18, 2026James F. Cummings
Chief Medical Officer
FTax withholding
Common Stock
-6,772$0.63$4,298958,020Mar 20, 2026
Mar 18, 2026Steven Lo
President, Chief Exec Officer
FTax withholding
Common Stock
-22,425$0.63$14k2,611,634Mar 20, 2026
Mar 18, 2026Sean Tucker
SVP, Chief Scientific Officer
FTax withholding
Common Stock
-8,072$0.63$5,122923,153Mar 20, 2026
Mar 16, 2026Sean Tucker
SVP, Chief Scientific Officer
AGrant or award
Common Stock
+200,000$0.00$0931,225Mar 18, 2026
Mar 16, 2026Edward B Berg
SVP, General Counsel
AGrant or award
Common Stock
+115,000$0.00$0799,858Mar 18, 2026
Mar 16, 2026James F. Cummings
Chief Medical Officer
AGrant or award
Common Stock
+227,000$0.00$0964,792Mar 18, 2026
Mar 16, 2026Jeroen Nicolaas Grasman
Chief Financial Officer
AGrant or award
Common Stock
+227,000$0.00$0577,000Mar 18, 2026
Mar 16, 2026Steven Lo
President, Chief Exec Officer
AGrant or award
Common Stock
+846,500$0.00$02,634,059Mar 18, 2026
Mar 16, 2026Edward B Berg
SVP, General Counsel
AGrant or award
Stock Option (right to buy)derivative
+225,000$0.00$0225,000Mar 18, 2026
Mar 16, 2026James F. Cummings
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+455,000$0.00$0455,000Mar 18, 2026
Mar 16, 2026Jeroen Nicolaas Grasman
Chief Financial Officer
AGrant or award
Stock Option (right to buy)derivative
+455,000$0.00$0455,000Mar 18, 2026
Mar 16, 2026Steven Lo
President, Chief Exec Officer
AGrant or award
Stock Option (right to buy)derivative
+1,543,000$0.00$01,543,000Mar 18, 2026
Mar 16, 2026Sean Tucker
SVP, Chief Scientific Officer
AGrant or award
Stock Option (right to buy)derivative
+410,000$0.00$0410,000Mar 18, 2026
Feb 2, 2026Edward B Berg
SVP, General Counsel
FTax withholding
Common Stock
-9,265$0.61$5,638684,858Feb 5, 2026
Feb 2, 2026James F. Cummings
Chief Medical Officer
FTax withholding
Common Stock
-7,965$0.61$4,847737,792Feb 5, 2026
Feb 2, 2026Sean Tucker
SVP, Chief Scientific Officer
FTax withholding
Common Stock
-9,265$0.61$5,638731,225Feb 5, 2026
Dec 4, 2025Steven Lo
President, Chief Exec Officer
AGrant or award
Common Stock
+151,351$0.00$01,841,712Dec 8, 2025
Dec 4, 2025Steven Lo
President, Chief Exec Officer
FTax withholding
Common Stock
-54,153$0.37$20k1,787,559Dec 8, 2025
Nov 17, 2025W. Mark Watson
director
POpen-market purchase
Common Stock
+15,000$0.41$6,150119,125Dec 5, 2025
Nov 17, 2025W. Mark Watson
director
POpen-market purchase
Common Stock
+5,000$0.41$2,035124,125Dec 5, 2025
Nov 17, 2025Elaine J Heron
director
POpen-market purchase
Common Stock
+23,217$0.39$9,12479,783Nov 21, 2025
Nov 17, 2025Elaine J Heron
director
POpen-market purchase
Common Stock
+16,783$0.41$6,79796,566Nov 21, 2025
Jul 17, 2025Kevin Finney
director
POpen-market purchase
Common Stock
+794$0.38$30238,897Aug 19, 2025
Jul 25, 2025Kevin Finney
director
POpen-market purchase
Common Stock
+20,000$0.39$7,80058,897Aug 19, 2025
Jul 28, 2025Kevin Finney
director
POpen-market purchase
Common Stock
+20,000$0.40$8,00078,897Aug 19, 2025
Jul 30, 2025Kevin Finney
director
POpen-market purchase
Common Stock
+25,874$0.38$9,832104,771Aug 19, 2025
Aug 15, 2025Kevin Finney
director
POpen-market purchase
Common Stock
+50,000$0.35$18k154,771Aug 19, 2025
Aug 15, 2025Kevin Finney
director
POpen-market purchase
Common Stock
+50,000$0.37$19k204,771Aug 19, 2025
Jul 29, 2025W. Mark Watson
director
POpen-market purchase
Common Stock
+10,000$0.41$4,050104,125Jul 31, 2025
50 of 79 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about VXRT

Answered from the filings on this page, as of the latest one.

Are insiders buying VXRT?

No. In the last 90 days no insider at Vaxart, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade VXRT on the open market?

W. Mark Watson (director) bought $6,530 of VXRT on May 22, 2026 and filed the Form 4 on May 26, 2026. InsiderTell scored 22 (weak).

How many insiders file Form 4 at Vaxart, Inc.?

10 people have filed a Form 4 at Vaxart, Inc., among them James B Breitmeyer (director), Edward B Berg (SVP, General Counsel), James F. Cummings (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

VXRT insider trading: Vaxart, Inc. | InsiderTell